mepolizumab
Sign in to saveAlso known as Bosatria, SB-240563
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- IL-5
- Drug.tradename
- Nucala
- Drug.MedlinePlus
- a615058
- Drug.DailyMedID
- Mepolizumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous injection
- Drug.ATC_prefix
- R03
- Drug.ATC_suffix
- DX09
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 80% (estimate)
- Drug.protein_bound
- None
- Drug.metabolism
- Proteolytic enzymes
via Wikipedia infobox
Research
2,299 papers- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.The New England journal of medicine · 2017
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.The New England journal of medicine · 2017
- Mepolizumab treatment in patients with severe eosinophilic asthma.The New England journal of medicine · 2014
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Respiratory medicine · 2021
- Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.International journal of chronic obstructive pulmonary disease · 2021
via PubMed
~4 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Side effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- References
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
The most common side effects include headache, injection site reactions, and back pain.
Excerpted from Wikipedia’s “mepolizumab” article, available under the CC BY-SA 4.0 licence.